That certain HLA specificities are associated with predisposition to autoimmune disease does not necessarily imply that self-reactive T cells restricted to particular HLA alleles are eliciting the disease. In the present essay, we argue that HLA can be a major genetic factor in the development of autoimmune diseases without T cells being primarily involved in its initiation or perpetuation. There is now ample evidence that self-reactive, regulatory T cells can protect against pernicious autoimmunity. Hereafter, we propose that extended HLA haplotypes, such as DQ3-DR4, DQ3-DR9, DQ5-DR1 and DQ5-DR10 in the case of rheumatoid arthritis, predispose to impaired T-cell-mediated immune regulation. The haplotypes associated with impaired regulation are the combination of certain class II alleles and a yet unknown 'amplifier'. In this model, products of the HLA class II region are not involved in the presentation of particular organ-specific autoantigens. Therefore, HLA does not predispose to autoimmune disease per se, but rather fails to provide efficient protection.
A central dogma in immunology is that T and B cells lymphocytes in the joint infiltrates, the production of the so-called rheumatoid factor (RF ) by B cells, and the provide the specificity of an immune response.
Immunologists have built upon this idea a model of association of certain HLA specificities with disease susceptibility. However, attempts to identify T-cellautoimmunity that is also centred on the crucial role of autoantigen-specific T and B cells. The association of specific determinants associated with the disease have been fruitless. Therefore, questions about the role of certain HLA specificities or alleles with autoimmune diseases has been regarded as evidence that autoreactive T cells in the immunopathogenesis of RA have been raised regularly [1] . Synovial T cells are hyporesponsive, T lymphocytes should be major histocompatibility complex (MHC )-restricted and recognize particular and this chronic dysfunction is due to the accumulation of oxidative agents in the synovium [2] . As a result, self-determinants. Disappointingly, more than 20 yr of intensive research has yielded little evidence for this these T lymphocytes produce low amounts of cytokines such as interleukin (IL)-2, IL-4, IL-5 and interferon concept.
(IFN )-c when cultured in vitro. It is difficult to imagine that such hyporesponsive cells could play an active role An example: rheumatoid arthritis in the perpetuation of RA, and the disappointing results observed with anti-T cell monoclonal antibody therapies Rheumatoid arthritis (RA) is a chronic inflammatory disease that mostly affects the joints, although systemic are consistent with this idea [3, 4] . manifestations are frequent. It starts with inflammation of the synovial membrane and often leads to the erosive destruction of adjacent cartilage and bone. It is a highly Synoviocytes and RA heterogeneous disease of unpredictable prognosis. The As a consequence, there has been renewed interest in cause of RA remains unknown and its pathophysiology the role of synoviocytes in the pathogenesis of RA. is controversial. Although it is undoubtedly characterThere are two types of synoviocytes, referred to as types ized by autoaggression, the belief that it is autoimmune A and B. Type A synoviocytes are macrophage-like in nature is based mainly on the large proportion of whereas type B are fibroblast-like [5] . They normally form a lining one or two cells deep at the interface between the synovium and the intra-articular space. In synoviocytes and macrophages produce large quantities of proteases, which are responsible for the destruction However, without mycobacterial extract in the adjuvant, these mice rarely develop disease, suggesting that joint of the underlying cartilage and bone [6 ] . The hyperplasia is often regarded as a consequence of the production of inflammation is first induced by mycobacterial components and then exacerbated by CII-specific T cells. cytokines by inflammatory cells, which is itself sustained by activated T cells. It is also not considered to be T cells are not always sufficient or necessary to elicit autoimmunity. In mice expressing a liver-specific MHC RA-specific as it has been observed in reactive arthritis and osteoarthritis. However, synoviocytes in RA class I allele, autoreactive T cells against this antigen do not induce autoimmune disease without infection with patients are autonomous, to a great extent because of their autocrine regulation by IL-6 [7] , a target of interest Listeria monocytogenes [14] . T-cell receptor-deficient MRL mice develop a lupus-like disease with hypergamin the treatment of RA. Since synoviocytes are probably derived from monocyte precursors in the bone marrow, maglobulinaemia and autoantibodies against DNA and ribonucleoproteins [15] . Human type B synoviocytes it has been suggested that RA is a bone marrow disorder [8] .
engrafted into SCID mice induce pannus formation with cartilage invasion in the absence of T and B lymphocytes The transformed phenotype of RA synoviocytes has led to the concept that these fibroblast-like cells could [16 ] . Some strains of mice can develop spontaneous, severe arthritic lesions without lymphocytes in the be 'transformed aggressors' rather than merely 'passive responders' [5] . Retroviruses and up-regulated protojoints [17] . oncogenes have been implicated in the causation of RA [9] ; the fact that the HTLV-I virus can induce an Autoreactive T cells protect against RA-like disease supports this [10] . Interestingly, highly autoimmune disease differentiated synovial T cells are surprisingly resistant to apoptosis [11] , and RA fibroblasts have been implicEhrlich's concept of 'horror autotoxicus' has been seriously challenged in recent years. The two major points ated in this rescue from apoptosis [11] . In this scheme, and in sharp contrast to common belief, T cells would relevant to this essay are (i) that self-reactive T cells are not necessarily deleted during thymic education, and (ii) become 'passive bystanders' at the chronically inflamed RA synovium.
that these T cells can protect against autoimmunity.
The general concept emerging from recent observa-A unique feature of the RA synovium is the formation of germinal centres. In normal lymphoid follicles these tions in experimental models is that 'anergic, naive' T cells in the periphery are regulatory T cells that are germinal centres contain follicular dendritic cells (FDCs), which can induce immunoglobulin isotype constantly stimulated by their specific autoantigen [18, 19] . These T cells can protect against autoimmune disswitching in B cells and the maturation of plasma cells. Interestingly, it has been shown recently that type B ease efficiently, by producing either transforming growth factor ( TGF )-b or IL-10. They are therefore similar or synoviocytes from RA patients have the intrinsic characteristics of FDCs [12] . This finding could explain the identical to the IFN-c-and IL-10-producing CD4+ Tr1 cells generated in vitro in the presence of IL-10 [20]. polyclonal activation of memory B cells, producing large amounts of non-joint-specific autoantibodies such as
What makes an autoantigen a potential target for regulatory T cells remains to be clarified. Candidates of RF and antibodies against citrulline-containing determinants [13] . In this scheme, B-cell activation would be interest are peptides derived from ubiquitous proteins that are over-expressed during inflammation and highly secondary to the abnormal transformation of type B synoviocytes into FDCs.
conserved during evolution, such as heat-shock proteins (Hsps) and the human cartilage glycoprotein (gp) Other loci besides HLA class II clearly contribute to the association of certain HLA haplotypes with autoimmune DQ3 (DQB1*03/DQA1*03 and DQB1*04/DQA1*03 in Asians) is in linkage disequilibrium with the DR4 disease. Microsatellite analysis of the D6S273 and D6STNFa loci has shown that an additional locus inside and DR9 alleles and DQ5 (DQB1*0501/ DQA1*0101(4)) with the DR1 and DR10 alleles.
the HLA class III region contributes to RA susceptibility [37] . We have found that homozygosity for the Table 1 shows that DQ3-and DQ5-related haplotypes are both associated with RA, but in a distinct fashion.
D6STNFa2 allele is strongly associated with RA among DQ2-DR3/DQ3-DR4 heterozygotes [38] and with more DQ3/3 homozygotes, but not DQ3/5 heterozygotes, are significantly more at risk of developing RA than DQ3/x active disease among early DQ5/x arthritic patients. Therefore, an extended MHC haplotype rather than a individuals. DQ5/5 homozygotes tend to be more predisposed to RA than DQ5/x individuals. Protective DRB1 particular class II locus predisposes to RA. Similar conclusions have been drawn from studies in other alleles carrying the motif DERAA in their third hypervariable region can overcome the DQ5-related predisautoimmune diseases, such as type I diabetes [39] . A model involving two (or more) distinct subregions position (DQ5/DERAA versus DQ5/x; Table 1 aDQ3/3, DQ5/5 and DQ3/5 represent individuals with two doses of predisposing DQ alleles, DQ3/x and DQ5/x represent individuals with a single dose, and DQ5/DERAA represents individuals with one dose of the predisposing DQ5 allele along with a protective DERAA allele. DQ3 alleles are the combinations of DQB1*03 (DQB1*04 in Asians) with DQA1*03 (but not DQA1*0501), DQ5 alleles are the combinations of DQB1*0501 with DQA1*0101(4), and DERAA-positive DRB1 alleles are *0103, *0402, *1102, *1103, *1301 and *1302.
bDiagnosis at 1 yr follow-up in an early arthritis clinic. cCadaveric organ donors. dDQx/x individuals are used as reference.
DQB1-DQA1-DRB1 complex, encoding antigen-HLA fails to protect rather than predisposes presenting molecules (including self-antigen-presenting Hereafter, we will describe a model in which self-reactive molecules) and playing an essential role in immunoregul-T cells regulate RA susceptibility but do not play an ation, constitutes one such subregion. In this context, active role in the disease process (Fig. 2) . DQ3 alleles are strongly associated with impaired T-cellThe initial event in RA is the activation of synomediated dysregulation. This genetic defect is transmitviocytes after trauma or infection. In most cases, this ted as a recessive trait and is therefore overcome by local inflammation subsides within days. However, one most HLA class II haplotypes. In this model, DQ3 or more genetic factors, inside and outside the HLA molecules have impaired presentation of self-peptides, region, are associated with aberrant activation of synovieither because of the particular instability of the HLAocytes, leading to their hyperplasia and a more chronic peptide complexes [40] or because of an abnormality in disease. The resulting production of large amounts of the regulation of gene expression [41] . On the other cytokines, such as IL-15 [43], can recruit inflammatory hand, DQ5 is either neutral or only moderately associcells in the joint. As extensively discussed by Thomas ated with this dysregulation.
and Lipsky [44] , the chemoattraction of dendritic cells The actual locus (or loci) involved in the second (DCs) from the periphery into the synovium and subregion remains to be identified, but the TNF-a gene draining lymph nodes, or the recently proposed transis a possible candidate in view of the beneficial effect of formation of synoviocytes into FDCs, is a key event in therapies against this cytokine [42] . An 'amplifier' factor the mutation of a local inflammation into a more chronic in this region predisposes to abnormal and limited disease. We agree that endogenous self-peptides preinflammation, independently of HLA class II. However, sented by DCs play an important role in RA [44] . it is found in linkage disequilibrium with both However, we propose that their function is not to DQ3-DR4-and DQ5-DR1/10-related haplotypes and promote disease but rather to interfere with its progrestherefore contributes strongly to the association of these sion. The amplifier would be an important genetic factor haplotypes with RA. In particular, it has an important in this attraction of DCs to the joints or, more generally confounder effect in the observed association of DQ5 speaking, to the exacerbation of the inflammation. with both RA and unclassified arthritis. Because DQ5
Along with DCs, self-reactive regulatory T cells recogby itself is not or is only weakly associated with impaired nizing determinants such as MHC peptides (DERAA) immunoregulation, DERAA-bearing DRB1 alleles are recruited ( Fig. 2) . This interaction between DCs and can provide dominant and efficient protection in regulatory T cells constitutes an essential checkpoint in DQ5/DERAA individuals ( Table 1) . It should be noted the control of the ongoing autoaggression. DCs indeed that the same additive effect of the DQ5-DR1 haplotypes express high levels of self-peptides, including self-MHC in susceptibility to autoimmunity is also observed in peptides [45] , and play an active role in the maintenance type I diabetes and sarcoid arthritis [36 ] . of peripheral tolerance [46 ] . They are the major antigenThe distribution of the four genetic markers (DQ3, presenting cells in the autologous mixed lymphocyte DQ5, DERAA and the amplifier) on three loci in linkage reaction, and a deficiency in this reaction is associated disequilibrium and on two chromosomes accounts for the complex association of HLA with RA (Fig. 1) .
with disease activity in autoimmune diseases such as F. 1. Distributions of the four RA-predisposing factors (DQ3, DQ5, DERAA and the amplifier) in extended HLA haplotypes and representative genotypes. Transcomplementation between the four factors in diploid individuals accounts for the complexity of the association of HLA with RA.
F. 2.
Loss of immunoregulation by self-peptide-specific regulatory T-cells leads to autoimmune disease. The initial hyperplasia of the synovial membrane amplified in an autocrine fashion leads to the attraction of DCs, which in turn recruit regulatory T cells. In most cases, the resulting interaction prevents further inflammation. Abnormal T-cell regulation associated with certain HLA extended haplotypes, i.e. DQ3-DR4, DQ3-DR9, DQ5-DR1 and DQ5-DR10, leads to the loss of self-tolerance followed by polyclonal activation of T and B cells.
RA [47] . The concomitant exacerbation of the inflamre-establishing a normal phenotype in synoviocytes or on restoring a functional immunoregulatory loop. matory process under the control of the amplifier and the failure of DQ3-and DQ5-restricted regulatory T cells $ More than 50% of the genetic predisposition to RA is not HLA-linked, and a significant part is probably to provide protection lead to at least local loss of tolerance. This in turn can provide help in the polyclonal represented by genes involved in the early phase of disease. Attempts to identify these genes should activation of B-cells, leading to the production of autoantibodies such as RF. Joint-specific T cells might include patients with remitting undifferentiated arthritis, osteoarthritis or reactive arthritis. be generated in the process. However, they are not a prerequisite and they are not necessarily restricted by $ The analysis of extended MHC haplotype conformation in relation to RA should have a high priority. a particular HLA allele. DRB1*0401 might present a particular determinant(s), which would explain its assoFinally, we emphasize that our model is also relevant ciation with the most severe form of RA, although a to other autoimmune disorders. As studies in both mice confounder effect of a gene in linkage disequilibrium and rats have shown [48] , common genes are probably cannot be excluded. This constant cross-activation of Binvolved in the pathology of many autoimmune diseases. and T-lymphocytes, monocytes, DCs and synoviocytes generates an amplification loop that leads to the chronicity of RA and its severity (Fig. 2) . $ The search for a common autoantigen in RA is irrelevant. University Medical Centre, The Netherlands) to the work described in this article. This work was supported $ Any attempt to interfere exclusively with T-cells in the pathogenesis of RA has no chance of success, and by The Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NOW ) and The Nederlandse Vereniging might even worsen the disease. $ Future therapies should concentrate either on voor Reumabestrijding.
